We rank companies based on fund manager, research analyst and news sentiment
ASLN

ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN

$0.51
0.92%
 

About: ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

Employees: 34

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

16% more funds holding

Funds holding: 19 [Q3] → 22 (+3) [Q4]

0.53% less ownership

Funds ownership: 1.39% [Q3] → 0.85% (-0.53%) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

83% less capital invested

Capital invested by funds: $10.5M [Q3] → $1.8M (-$8.7M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
1,681%
upside
Avg. target
$12
2,275%
upside
High target
$17
3,264%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
1,681%upside
$9
Buy
Reiterated
15 Apr 2024
HC Wainwright & Co.
Yi Chen
1,681%upside
$9
Buy
Maintained
18 Mar 2024
Piper Sandler
Edward Tenthoff
1,879%upside
$10
Overweight
Reiterated
13 Mar 2024
Piper Sandler
Edward Tenthoff
2,869%upside
$15
Overweight
Maintained
11 Mar 2024
HC Wainwright & Co.
Yi Chen
3,264%upside
$17
Buy
Reiterated
6 Nov 2023

Financial journalist opinion

Based on 3 articles about ASLN published over the past 30 days